PCA
ASND icon

Providence Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Providence Capital Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$6K – 290
2018
Q4 		$6K Hold
100
– – ﹤0.01% 207
2018
Q3 		$7K Hold
100
– – ﹤0.01% 208
2018
Q2 		$7K Hold
100
– – ﹤0.01% 200
2018
Q1 		$7K Buy
+100
New +$5.62K 0.01% 199

Other funds holding ASND

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Providence Capital Advisors's ASND Position: Q1 2019 in Review

Providence Capital Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2019, closing a stake of 100 shares — an estimated $6K sold.

Providence Capital Advisors first reported a position in ASND in Q1 2018 and held it in 4 quarters. The position peaked at $7K in Q3 2018. 138 funds tracked by Wall St. Rank hold ASND as of Q1 2019.

  • Providence Capital Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2019 after selling out during the quarter.
  • Providence Capital Advisors sold 100 Ascendis Pharma A/S shares in Q1 2019, an estimated $6K.
  • Providence Capital Advisors first reported a position in Ascendis Pharma A/S in Q1 2018 and held it in 4 quarters.
  • Providence Capital Advisors's Ascendis Pharma A/S position peaked at $7K in Q3 2018.
  • 138 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2019.

Based on Providence Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.